Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors

BACKGROUND: Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’ tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT as an immunotherapy across nine cancer types. METHODS: A phase 1 clinical trial was...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Vonderheide, Robert H, Kraynyak, Kimberly A, Shields, Anthony F, McRee, Autumn J, Johnson, Jennifer M, Sun, Weijing, Chintakuntlawar, Ashish V, Pawlicki, Jan, Sylvester, Albert J, McMullan, Trevor, Samuels, Robert, Kim, Joseph J, Weiner, David, Boyer, Jean D, Morrow, Matthew P, Humeau, Laurent, Skolnik, Jeffrey M
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Clinical/Translational Cancer Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8261871/
https://ncbi.nlm.nih.gov/pubmed/34230114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-003019
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars